King's College London

Research portal

Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature

Research output: Contribution to journalArticle

Standard

Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry : a Systematic Review of the Literature. / Mechler, Konstantin; Häge, Alexander; Schweinfurth, Nina; Glennon, Jeffrey C; Dijkhuizen, Rick M; Murphy, Declan; Durston, Sarah; Williams, Steven; Buitelaar, Jan K; Banaschewski, Tobias; Dittmann, Ralf W; Tactics Consortium, The.

In: ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 18.09.2017, p. 246-263.

Research output: Contribution to journalArticle

Harvard

Mechler, K, Häge, A, Schweinfurth, N, Glennon, JC, Dijkhuizen, RM, Murphy, D, Durston, S, Williams, S, Buitelaar, JK, Banaschewski, T, Dittmann, RW & Tactics Consortium, T 2017, 'Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature', ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, pp. 246-263. https://doi.org/10.1024/1422-4917/a000546

APA

Mechler, K., Häge, A., Schweinfurth, N., Glennon, J. C., Dijkhuizen, R. M., Murphy, D., ... Tactics Consortium, T. (2017). Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature. ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 246-263. https://doi.org/10.1024/1422-4917/a000546

Vancouver

Mechler K, Häge A, Schweinfurth N, Glennon JC, Dijkhuizen RM, Murphy D et al. Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature. ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE. 2017 Sep 18;246-263. https://doi.org/10.1024/1422-4917/a000546

Author

Mechler, Konstantin ; Häge, Alexander ; Schweinfurth, Nina ; Glennon, Jeffrey C ; Dijkhuizen, Rick M ; Murphy, Declan ; Durston, Sarah ; Williams, Steven ; Buitelaar, Jan K ; Banaschewski, Tobias ; Dittmann, Ralf W ; Tactics Consortium, The. / Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry : a Systematic Review of the Literature. In: ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE. 2017 ; pp. 246-263.

Bibtex Download

@article{5eb69f9b4e8e447fb0abe55e42695b49,
title = "Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature",
abstract = "OBJECTIVE: Research has implicated glutamatergic projections between the various frontal subregions in the pathogenesis of compulsivity and impulsivity. Reducing striatal glutamate release, or antagonising the action of glutamate at its receptors, may therefore represent viable treatment strategies. Several glutamatergic agents with regulatory approval for other indications are available and may be of potential benefit in the treatment of compulsivity/impulsivity in psychiatric disorders in paediatric patients.METHOD: This review was performed according to PRISMA guidelines and evaluates available scientific literature concerning the use of glutamatergic agents in these patients, in order to determine their reported effectiveness/efficacy and tolerability/safety.RESULTS: Out of a total of 1,426 publications, 21 trials examining six glutamatergic substances in patients with obsessive-compulsive disorder, autism spectrum disorders, and attention deficit/hyperactivity disorder were included.CONCLUSIONS: Trial designs as well as results were heterogeneous and thus comparability was limited. Available data support the hypothesis that glutamatergic agents are of potential value in the treatment of compulsivity/impulsivity in children and adolescents. Based on the data reviewed, memantine and N-acetylcysteine suggest the best risk-benefit profile for future trials. Riluzole should primarily be further investigated in adults. Clinical research of this nature is a key element of the TACTICS Consortium project funded by the European Union (FP7).",
keywords = "Journal Article",
author = "Konstantin Mechler and Alexander H{\"a}ge and Nina Schweinfurth and Glennon, {Jeffrey C} and Dijkhuizen, {Rick M} and Declan Murphy and Sarah Durston and Steven Williams and Buitelaar, {Jan K} and Tobias Banaschewski and Dittmann, {Ralf W} and {Tactics Consortium}, The",
year = "2017",
month = "9",
day = "18",
doi = "10.1024/1422-4917/a000546",
language = "English",
pages = "246--263",
journal = "ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE",
issn = "1422-4917",
publisher = "Verlag Hans Huber",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry

T2 - a Systematic Review of the Literature

AU - Mechler, Konstantin

AU - Häge, Alexander

AU - Schweinfurth, Nina

AU - Glennon, Jeffrey C

AU - Dijkhuizen, Rick M

AU - Murphy, Declan

AU - Durston, Sarah

AU - Williams, Steven

AU - Buitelaar, Jan K

AU - Banaschewski, Tobias

AU - Dittmann, Ralf W

AU - Tactics Consortium, The

PY - 2017/9/18

Y1 - 2017/9/18

N2 - OBJECTIVE: Research has implicated glutamatergic projections between the various frontal subregions in the pathogenesis of compulsivity and impulsivity. Reducing striatal glutamate release, or antagonising the action of glutamate at its receptors, may therefore represent viable treatment strategies. Several glutamatergic agents with regulatory approval for other indications are available and may be of potential benefit in the treatment of compulsivity/impulsivity in psychiatric disorders in paediatric patients.METHOD: This review was performed according to PRISMA guidelines and evaluates available scientific literature concerning the use of glutamatergic agents in these patients, in order to determine their reported effectiveness/efficacy and tolerability/safety.RESULTS: Out of a total of 1,426 publications, 21 trials examining six glutamatergic substances in patients with obsessive-compulsive disorder, autism spectrum disorders, and attention deficit/hyperactivity disorder were included.CONCLUSIONS: Trial designs as well as results were heterogeneous and thus comparability was limited. Available data support the hypothesis that glutamatergic agents are of potential value in the treatment of compulsivity/impulsivity in children and adolescents. Based on the data reviewed, memantine and N-acetylcysteine suggest the best risk-benefit profile for future trials. Riluzole should primarily be further investigated in adults. Clinical research of this nature is a key element of the TACTICS Consortium project funded by the European Union (FP7).

AB - OBJECTIVE: Research has implicated glutamatergic projections between the various frontal subregions in the pathogenesis of compulsivity and impulsivity. Reducing striatal glutamate release, or antagonising the action of glutamate at its receptors, may therefore represent viable treatment strategies. Several glutamatergic agents with regulatory approval for other indications are available and may be of potential benefit in the treatment of compulsivity/impulsivity in psychiatric disorders in paediatric patients.METHOD: This review was performed according to PRISMA guidelines and evaluates available scientific literature concerning the use of glutamatergic agents in these patients, in order to determine their reported effectiveness/efficacy and tolerability/safety.RESULTS: Out of a total of 1,426 publications, 21 trials examining six glutamatergic substances in patients with obsessive-compulsive disorder, autism spectrum disorders, and attention deficit/hyperactivity disorder were included.CONCLUSIONS: Trial designs as well as results were heterogeneous and thus comparability was limited. Available data support the hypothesis that glutamatergic agents are of potential value in the treatment of compulsivity/impulsivity in children and adolescents. Based on the data reviewed, memantine and N-acetylcysteine suggest the best risk-benefit profile for future trials. Riluzole should primarily be further investigated in adults. Clinical research of this nature is a key element of the TACTICS Consortium project funded by the European Union (FP7).

KW - Journal Article

UR - http://www.scopus.com/inward/record.url?scp=85046468531&partnerID=8YFLogxK

U2 - 10.1024/1422-4917/a000546

DO - 10.1024/1422-4917/a000546

M3 - Article

C2 - 28922069

SP - 246

EP - 263

JO - ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE

JF - ZEITSCHRIFT FUR KINDER UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE

SN - 1422-4917

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454